"Transarterial Microembolization (TAME) in Inflammatory Knee Pathology"

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorIstituto Ortopedico Rizzoli

About this trial

Patients with knee OA and chronic pain refractory to at least 3 months of conventional conservative therapy will be included in the study, which will evaluate the clinical results obtained after treatment with selective arterial embolization (selection and enrollment, treatment with selective arterial embolization, follow-up checks). Forty-three patients will be included in the study and will undergo the transarterial microembolization procedure after signing the informed consent form for participation in the study and the collection of anamnestic data. Subsequently, patients will be followed up with clinical evaluation at 1, 3, 6, 12, and 24 months of follow-up or until possible dropout for other treatment.

Eligibility criteria

Qualifiers

Age over 40 years;

Moderate knee OA (grade 2-3 according to the Kellgren-Lawrence score) for which an indication for total knee arthroplasty surgery has already been given;

Knee OA with an inflammatory component (night pain, pain at rest, recurrent episodes of effusion, swelling and/or redness);

Persistent and moderate or severe knee pain (VAS score > 4);

Disqualifiers

Mentally incompetent patients;

Patients with trauma in the 6 months prior to treatment;

Patients with malignant neoplasms;

Patients with rheumatic diseases;

Trial design

Treatments tested in this trial

  • Transarterial Microembolization

Treatment groups

43 Participants
are divided into 1 treatment group

Sponsors and collaborators

Istituto Ortopedico Rizzoli

Lead sponsor

Ospedale San Giuseppe Moscati, Avellino

Collaborator

Azienda Ospedaliero-Universitaria, Catania

Collaborator

Azienda Ospedaliera di Perugia

Collaborator

San Salvatore Hospital, AST Pesaro-Urbino

Collaborator

A.O.U. Città della Salute e della Scienza - Molinette Hospital

Collaborator